Compare Realty Income Corp (O) vs Sana Biotechnology Inc (SANA) Price & Performance

Realty Income (O) trades at $64.99, down 1.1% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported revenue of $5.75B in 2025 with a net income margin of 19.05%, though recent quarterly EPS results have missed expectations. Analyst consensus is a Hold with a $67.43 price target, and the stock offers a consistent dividend, recently paying $0.27 per share.

Outlook remains mixed; growth via partnerships and a high 5.14% yield are positives, but elevated P/E of 53.43 and consecutive EPS misses pose risks. Investors should weigh the reliable income stream against valuation concerns and interest rate sensitivity.

SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.

While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.